Sotera Health (SHC)
(Delayed Data from NSDQ)
$15.32 USD
+0.12 (0.79%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $15.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.32 USD
+0.12 (0.79%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $15.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Zacks News
CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
CareDx (CDNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Compared to Estimates, Sotera Health (SHC) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Sotera Health (SHC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sotera Health Company (SHC) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Sotera Health (SHC) delivered earnings and revenue surprises of 11.76% and 3.42%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs (ESTA) Surges 7.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Establishment Labs (ESTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Sotera Health Company (SHC) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Sotera Health (SHC) delivered earnings and revenue surprises of -7.14% and 2.57%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Sotera Health Company (SHC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Sotera Health (SHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sotera Health Company (SHC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Sotera Health Company (SHC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sotera Health Company (SHC) Meets Q4 Earnings Estimates
by Zacks Equity Research
Sotera Health Company (SHC) delivered earnings and revenue surprises of 0% and 3.23%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Unveiling Sotera Health Company (SHC) Q4 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Sotera Health Company (SHC) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Teladoc (TDOC) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 22.73% and 1.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Sotera Health Company (SHC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Sotera Health Company (SHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMN Healthcare Services (AMN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 4.76% and 1.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Compared to Estimates, Sotera Health Company (SHC) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Sotera Health Company (SHC) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sotera Health Company (SHC) Tops Q2 Earnings Estimates
by Zacks Equity Research
Sotera Health Company (SHC) delivered earnings and revenue surprises of 16.67% and 2.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Sotera Health Company (SHC): Can Its 17.3% Jump Turn into More Strength?
by Zacks Equity Research
Sotera Health Company (SHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Sotera Health Company (SHC) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Sotera Health Company (SHC) delivered earnings and revenue surprises of -7.14% and 0.05%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Life Time Group Holdings, Inc. (LTH) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Life Time Group Holdings, Inc. (LTH) delivered earnings and revenue surprises of 42.86% and 0.74%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sotera Health Company (SHC) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Sotera Health Company (SHC) delivered earnings and revenue surprises of 13.64% and 1.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ModivCare (MODV) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of 35.26% and 6.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sotera Health Company (SHC) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Sotera Health Company (SHC) delivered earnings and revenue surprises of 4.55% and 1.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sotera Health Company (SHC) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Sotera Health Company (SHC) delivered earnings and revenue surprises of 12.50% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sotera Health Company (SHC) Stock Jumps 6.5%: Will It Continue to Soar?
by Zacks Equity Research
Sotera Health Company (SHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Sotera Health Company (SHC) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Sotera Health Company (SHC) delivered earnings and revenue surprises of 15.79% and 2.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Sotera Health Company (SHC) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Sotera Health Company (SHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 1.48% and 0.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?